Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever [1]

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1307-1308

  Yuksel S ^a   Yalcinkaya F ^a   Acar, B ^a   Ozcakar Z B ^a   Ozturk B ^a   Ekim, M ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AMYLOIDOSIS; ANAMNESIS; BACTERIAL ARTHRITIS; CASE REPORT; CHILDHOOD DISEASE; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DUODENUM BIOPSY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY BIOPSY; LETTER; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RECTUM BIOPSY; RHEUMATIC FEVER; SCHOOL CHILD; TREATMENT OUTCOME; VOMITING;

AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; CHILD; COLCHICINE; DRUG THERAPY, COMBINATION; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 33749631976     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel250     Document Type: Letter

References (10)

1. Zemer D, Livneh A, Danon YI. Long term colchicine treatment in children with FMF. Arthritis Rheum 1991;34:973-7.
2. Cakar N, Yalcinkaya F, Ozkaya N et al. Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 2001; 19(Suppl 24):63-7.
3. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000; 343:1044-5.
4. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004; 43:1405-8.
5. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3.
6. Gottenberg JE, Merle-Vincent F, Bentaberry F et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.
7. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
8. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 2005;53:146-7.
9. Ozgocmen S, Ozcakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: Single case experience. Clin Rheumatol 2006;25:83-7.
10. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004;10:134-7.